Drug Companies Update June 2009
Mergers, acquisitions & Joint Ventures
- Accera has spun out Neuera Pharmaceuticals, which will operate as a wholly-owned subsidiary focused on the small molecule drugs for neurological conditions.
- Apotex has acquired Cangene, which remains as a subsidiary.
- CV Therapeutics has been acquired by Gilead Sciences as a subsidiary.
- Virionyx has changed its name and will henceforth be known as Innate Therapeutics.
New Companies
- Anergis is using its Contiguous Overlapping Peptides platform to develop immunotherapies for the treatment of allergies.
- Applied Protein Sciences is a biotech company focused on the treatment and prevention of chemotherapy-induced mucositis.
- Autoimmune Technologies is developing antiviral peptides based on technology licensed from Tulane University School of Medicine.
- Biomed Research & Technologies is developing a therapy for atopic dermatitis.
- Bio-Path Holdings is involved in the development of novel anticancers.
- Epitomics is developing antibody therapeutics using its proprietary RabMab technology.
- ImmunoVaccine Technologies is developing therapeutic cancer vaccines and prophylactic infectious disease vaccines.
- Inagen is an antiviral company.
- Intezyne Technologies is utilising its IVECT delivery platform to further develop currently available but hard-to-administer drugs.
- LiPlasome is a biotech outfit working on novel lipid-based prodrugs and delivery platforms.
- Marinomed specialises in research on marine organisms to develop innovative drugs.
- MedCell BioScience is concerned with the development of stem cells to provide musculoskeletal regenerative therapies.
- NeuroScience Pharmaceuticals develops drugs for brain-related disorders.
- Okairos is developing genetic vaccines for chronic infectious diseases using adenoviral vectors to deliver therapeutic antigens.
- Pantec Biosolutions is using its PLEASE platform to enable needle-free delivery of therapeutics.
- PepTx discovers and develops novel peptides, partial peptide mimetics and related small molecules.
- Pulmatrix is developing a new class of inhaled therapies for respiratory disease.
- Replikins is focused on the development of synthetic vaccines.
- Revance is developing and commercialising treatments in dermatological and aesthetic medicine.
- Rockwell Medical Technologies is developing a treatment for end-stage renal failure.
- Tokai Pharmaceuticals is a company focusing on therapies for hormone-dependant growth disorders.
- Ventrus Biosciences is a specialty pharmaceutical company focused on the development and commercialisation of licensed, late-stage gastrointestinal products in areas of unmet medical need.
- VeroScience is developing therapies for chronic debilitating diseases in the areas of metabolism, immunology and oncology.
